BioCentury | Nov 13, 2019
Finance
Allievex, backed by Pappas and Novo, scoops up BioMarin ultra-rare disease assets
...Corp. holds an exclusive, worldwide license from BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) to tralesinidase alfa (formerly BMN 250...
...near term. Targets IGF-2 - Insulin-like growth factor 2 NAGLU - N-acetylglucosaminidase α Paul Bonanos, Associate Editor BMN 250 BioMarin...
...near term. Targets IGF-2 - Insulin-like growth factor 2 NAGLU - N-acetylglucosaminidase α Paul Bonanos, Associate Editor BMN 250 BioMarin...